187 related articles for article (PubMed ID: 32973147)
1. Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma.
Wang L; Huang X; You X; Yi T; Lu B; Liu J; Lu G; Ma M; Zou C; Wu J; Zhao W
Signal Transduct Target Ther; 2020 Sep; 5(1):196. PubMed ID: 32973147
[TBL] [Abstract][Full Text] [Related]
2. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
4. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Notch signaling pathway attenuates progression of cell motility, metastasis, and epithelial-to-mesenchymal transition-like phenomena induced by low concentrations of cisplatin in osteosarcoma.
Dai G; Liu G; Zheng D; Song Q
Eur J Pharmacol; 2021 May; 899():174058. PubMed ID: 33757752
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line.
Martins-Neves SR; Lopes ÁO; do Carmo A; Paiva AA; Simões PC; Abrunhosa AJ; Gomes CM
BMC Cancer; 2012 Apr; 12():139. PubMed ID: 22475227
[TBL] [Abstract][Full Text] [Related]
7. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
8. β-Elemonic acid inhibits the growth of human Osteosarcoma through endoplasmic reticulum (ER) stress-mediated PERK/eIF2α/ATF4/CHOP activation and Wnt/β-catenin signal suppression.
Zhao A; Zhang Z; Zhou Y; Li X; Li X; Ma B; Zhang Q
Phytomedicine; 2020 Apr; 69():153183. PubMed ID: 32113150
[TBL] [Abstract][Full Text] [Related]
9. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
10. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
Mongre RK; Sodhi SS; Ghosh M; Kim JH; Kim N; Park YH; Kim SJ; Heo YJ; Sharma N; Jeong DK
Int J Oncol; 2015; 46(6):2573-85. PubMed ID: 25872586
[TBL] [Abstract][Full Text] [Related]
11. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
13. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells.
Chen F; Zeng Y; Qi X; Chen Y; Ge Z; Jiang Z; Zhang X; Dong Y; Chen H; Yu Z
Nanomedicine; 2018 Oct; 14(7):2115-2127. PubMed ID: 29898423
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma.
Zeng WN; Yu QP; Wang D; Liu JL; Yang QJ; Zhou ZK; Zeng YP
J Nanobiotechnology; 2021 Mar; 19(1):79. PubMed ID: 33740998
[TBL] [Abstract][Full Text] [Related]
15. CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma.
Wang Z; Yin F; Xu J; Zhang T; Wang G; Mao M; Wang Z; Sun W; Han J; Yang M; Jiang Y; Hua Y; Cai Z
J Exp Clin Cancer Res; 2019 Jan; 38(1):44. PubMed ID: 30704503
[TBL] [Abstract][Full Text] [Related]
16. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
17. Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells via Reactive Oxygen Species-Mediated Apoptosis and Autophagy.
Zhao B; Luo J; Wang Y; Zhou L; Che J; Wang F; Peng S; Zhang G; Shang P
Oxid Med Cell Longev; 2019; 2019():9290728. PubMed ID: 31827709
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitive effects of Astragaloside IV in osteosarcoma cells via induction of apoptosis and regulation of caspase-dependent Fas/FasL signaling.
Hu T; Fei Z; Wei N
Pharmacol Rep; 2017 Dec; 69(6):1159-1164. PubMed ID: 29128795
[TBL] [Abstract][Full Text] [Related]
20. Tideglusib suppresses stem-cell-like features and progression of osteosarcoma by inhibiting GSK-3β/NOTCH1 signaling.
Wei D; Zhu X; Li S; Liu G; Wang Y; Wang W; Zhang Q; Jiang S
Biochem Biophys Res Commun; 2021 May; 554():206-213. PubMed ID: 33813076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
